Home
Live Updates
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation : comparemela.com
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II variation approval of NILEMDO® Tablet and NUSTENDI® Tablet...
Related Keywords
Japan ,
Netherlands ,
United States ,
New York ,
Spain ,
Japanese ,
Sheldon Koenig ,
Daiichi Sankyo Europe ,
Daiichi Sankyo Europe Gmb ,
Daiichi Sankyo ,
Oliver Appelhans ,
Esperion Therapeutics Inc ,
Nasdaq ,
Daiichi Sankyo Co Ltd ,
European Medicines Agency ,
United States District Court ,
Esperion Therapeutics ,
Daiichi Sankyo Europe Gmbh ,
Southern District ,
Specialty Business Unit ,
Markets ,
comparemela.com © 2020. All Rights Reserved.